The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

820 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-01

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The patients who accepted the quadruple eradication program of the helicobacter pylori but failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication time of helicobacter pylori.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

NCT05173493

Helicobacter Pylori Infection

COMPLETED

The Effect of Time Intervals for Rescue Treatment on Eradication Effect of Helicobacter Pylori Infection

NCT05620589

Helicobacter Pylori Infection

UNKNOWN

Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection

NCT05176821

H. Pylori Infection

UNKNOWN NA

A Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

NCT05493644

Helicobacter Pylori Infection

UNKNOWN

Helicobacter Pylori Eradication and Follow-up

NCT05061732

Helicobacter Pylori Infection

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Helicobacter pylori (HP) infection is a common global infectious disease, which is an important cause of chronic gastritis, peptic ulcer and gastric cancer.

At present, due to the non-standard Helicobacter pylori eradication program in clinical work, poor patient compliance and other reasons, the phenomenon of HP eradication treatment failure is more and more common. However, there is still no conclusion on the most appropriate time for remedial treatment in patients with Hp eradication failure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Helicobacter Pylori

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amoxicillin-Levofloxacin-Esomeprazole-containing quadruple group

Patients in amoxicillin-levofloxacin-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d.

Amoxicillin , Levofloxacin and Esomeprazole

Intervention Type DRUG

Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens

Amoxicillin-Furazolidone-Esomeprazole-containing quadruple group

Patients in amoxicillin-furazolidone-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.

Amoxicillin , Furazolidone and Esomeprazole

Intervention Type DRUG

Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens

Tetracycline-Furazolidone-Esomeprazole-containing quadruple group

Patients in tetracycline-furazolidone-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, tetracycline 500mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.

Tetracycline , Furazolidone and Esomeprazole

Intervention Type DRUG

Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens

Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group

Patients in amoxicillin-levofloxacin-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d.

Amoxicillin,Levofloxacin and Vonoprazan fumarate

Intervention Type DRUG

Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group

Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group

Patients in amoxicillin-furazolidone-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.

Amoxicillin,Furazolidone and Vonoprazan fumarate

Intervention Type DRUG

Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group

Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group

Patients in tetracycline-furazolidone-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, tetracycline 500mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.

Tetracycline,Furazolidone and Vonoprazan fumarate

Intervention Type DRUG

Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amoxicillin , Levofloxacin and Esomeprazole

Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens

Intervention Type DRUG

Amoxicillin , Furazolidone and Esomeprazole

Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens

Intervention Type DRUG

Tetracycline , Furazolidone and Esomeprazole

Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens

Intervention Type DRUG

Amoxicillin,Levofloxacin and Vonoprazan fumarate

Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group

Intervention Type DRUG

Amoxicillin,Furazolidone and Vonoprazan fumarate

Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group

Intervention Type DRUG

Tetracycline,Furazolidone and Vonoprazan fumarate

Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients, aged between 18 and 70 years old, with positive H. pylori infection that was eradicated by previous therapies but failed are included. The H. pylori infection is confirmed by the positive rapid urease test or 13C-breath test.

Exclusion Criteria

* Patients with significant underlying disease including liver, cardiac, pulmonary, and renal diseases, neoplasia, coagulopathy and genetic diseases, history of gastric surgery, pregnancy, breast-feeding, active gastrointestinal bleeding, the use of PPI, NSAID or antibiotics during the 4 weeks prior to enrolment, and previous history of allergic reactions to any of the medications used in this protocol. Patients previously treated with H. pylori eradication regimens or those unwilling to participate in the study were also excluded.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes